Menopause
Surgery for pelvic organ prolapse tied to long-term reoperation risk for older women
Different surgical approaches to apical pelvic organ prolapse were significantly associated with different long-term risks for reoperation among women aged 65 years or older, according to study results published in Obstetrics & Gynecology.
VIDEO: With menstrual irregularity, consider primary ovarian insufficiency
In this video exclusive, Caroline T. Nguyen, MD, talks with Cynthia A. Stuenkel, MD, MSCP, about diagnosing primary ovarian insufficiency, a condition similar to but different from menopause among women younger than 40 years.
Navigating menopausal hormone therapy as CVD risk grows requires ‘nuanced approach’
For women experiencing disruptive, bothersome hot flashes, the use of menopausal hormone therapy — a one-time standard but later feared treatment option — is far from straightforward.
Purified pollen extract efficacy uncertain, but likely safe in reducing vasomotor symptoms
The therapeutic efficacy of purified pollen extract in reducing vasomotor and other perimenopausal symptoms is questionable, but is likely safe, according to a systematic review and meta-analysis published in Menopause.
Urinary incontinence significantly associated with disability for midlife women
For midlife women, urinary incontinence has a strong association with multiple disability domains, including mobility and social engagement, according to study findings published in Menopause.
Heavy metals tied to anti-Müllerian hormone levels, faster decline at menopause transition
Exposure to heavy metals, such as arsenic, cadmium and mercury, was associated with lower anti-Müllerian hormone concentrations and/or increased decline during the menopause transition, researchers reported.
Top in women’s health: Updates on hot flash treatments, postpartum hypertension
Fezolinetant performed better than other nonhormonal medications at reducing vasomotor symptoms due to menopause, according to a recent meta-analysis of randomized studies.
Elinzanetant’s impact on vasomotor symptoms prompts study on menopausal sleep disturbances
Following positive topline data for moderate to severe vasomotor symptom treatment, a phase 2 study of elinzanetant is underway to assess its safety and efficacy on sleep disturbances associated with menopause, Bayer said in a news release.
Fezolinetant associated with reduced hot flash frequency vs. other nonhormone therapies
Fezolinetant 45 mg once daily was statistically significantly more effective in reducing moderate to severe vasomotor symptom frequency compared with other nonhormonal — but not hormone-based — therapies in the U.S., researchers reported.
Statins could mitigate clotting risk in women at menopausal age on hormone therapy
Statin therapy could lower the odds of blood clot formation conferred by hormone therapy in perimenopausal women, according to a case-control study published in JAMA Network Open.